Connecting The Dots Between Diversity, Empowerment And Business Growth

‘Seeing Is Believing’ – Achievements Are There To Be Emulated Says Thermo Fisher Scientific Business Leader

Urmi Prasad Richardson brings a wealth of science and business experience to diagnostics and life sciences multinational Thermo Fisher Scientific, where for the past two years she has been president of the group’s vast and varied EMEA business. The Indian-born, Germany-based executive has surmounted a range of challenges along the way and offers her story as inspiration for others.

Shutterstock

More from Rising Leaders

Schumacher Looks To Steer Tubulis To The Top Of The ADC Tree

 
• By 

It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.

DISCO Pharma’s Surfaceome Technology Unlocks Novel Cancer-Selective Targets

 
• By 

Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.  

The Biotech Balancing Act: Long-Term Vision Vs. Inflection Points

 
• By 

Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.   

VC Insights On Future Tech And Future Leaders

 

“I'm a strong believer in creating the right mix between young ambitious people and pairing them up with someone experienced,” says Jeroen Bakker, who is focused on biotech company creation at Seed Investments, Novo Holdings.      

More from Leadership

Taking The Temperature Of UK Biotech 2025

 
• By 

With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?

Q&A: Rentschler’s CEO On The CDMO’s Pivot Away From Cell And Gene Therapy And More

 
• By 

Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.

20 Voices: What Does 2025 Hold For Biopharma?

 

Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.